To assess the associations of semaglutide with incident CUD (first time diagnosis of CUD), the study population included 83,189 patients who had active medical encounters for the diagnosis of obesity in 6/202112/2022, were for the first time (new users design) prescribed semaglutide or non-GLP-1RA anti-obesity medications (bupropion, naltrexone, orlistat, topiramate, phentermine) [39] during 6/2021-12/2022 (time zero or index event), had no diagnosis of CUD on or before the index event and had a diagnosis of at least one of obesity-associated comorbidities (T2D, hypertension, hypercholesterolemia, hyperlipidemia, heart diseases, stroke) on or before the index event
WW claims that in a real-world comparative analysis, its members achieved 72% greater average weight loss than a cohort receiving compounded GLP-1 medications through Hims & Hers
Are compounded GLP-1s safe after the February 2026 FDA warning letters
Conception, potentially delaying your period by preventing its onset, requires fertilization during ovulation
At the maintenance dose of 2.4mg, it lasts barely two weeks
Distinguishing between quality of life and health status in quality of life research: a meta-analysis